Trigeminal neuralgia

Noema Pharma Receives FDA Fast Track Designation for basimglurant (NOE-101) in Trigeminal Neuralgia

Retrieved on: 
Tuesday, October 18, 2022
Physician, Tourette syndrome, Disease, Columbia University Irving Medical Center, Review, IND, Tuberous sclerosis complex tumor suppressors, US Foods, Glutamate (neurotransmitter), PDE10A, Trigeminal nerve, Patient, Investigational New Drug, Pain management, Seizure, Addiction medicine, Food, Trigeminal neuralgia, Neurology, Company, Basimglurant, Sofinnova, Pain, Face, Safety, Adult, Neuropathic pain, CNS, GLOBE, Fast Track, Brain, Polaris Partners, FDA, Principal, Pharmaceutical industry, Anesthesia, Biotechnology

BASEL, Switzerland, Oct. 18, 2022 (GLOBE NEWSWIRE) -- Noema Pharma, a clinical-stage biotech company targeting debilitating central nervous system (CNS) indications, today announces that the US Food and Drug Administration (FDA) has granted Fast Track designation to its mGluR5 inhibitor basimglurant (NOE-101) for the treatment of trigeminal neuralgia (TN).

Key Points: 
  • BASEL, Switzerland, Oct. 18, 2022 (GLOBE NEWSWIRE) -- Noema Pharma, a clinical-stage biotech company targeting debilitating central nervous system (CNS) indications, today announces that the US Food and Drug Administration (FDA) has granted Fast Track designation to its mGluR5 inhibitor basimglurant (NOE-101) for the treatment of trigeminal neuralgia (TN).
  • "We are very pleased to receive Fast Track designation from the FDA, which is intended to bring promising medicines to patients sooner, and very much underlines the potential of basimglurant in pain management associated with TN," said George Garibaldi MD, President, Head of R&D of Noema Pharma.
  • The FDA authorized Noema Pharma's Investigational New Drug (IND) application to initiate a Phase 2/3 clinical trial of basimglurant in TN in February 2022.
  • Basimglurant, an mGluR5 inhibitor, is Phase 2b-ready for two indications: persistent seizures in Tuberous Sclerosis Complex and severe pain in Trigeminal Neuralgia.

American Shared Hospital Services to Present at the LD Micro Main Event XV

Retrieved on: 
Monday, October 17, 2022
SAN, CA, CFO, Radiosurgery, NYSE, Dream, LD, Index, Pectus carinatum, Malignancy, Company, Proton therapy, CEO, Trigeminal neuralgia, IGRT, AMS, GLOBE, IMRT, Medical imaging

SAN FRANCISCO, CA, Oct. 17, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – American Shared Hospital Services (NYSE American: AMS) (the “Company”), a leading provider of turnkey technology solutions for stereotactic radiosurgery and advanced radiation therapy equipment, facilities, and services, today announced that it will be presenting at the15th Annual Main Event being held on October 25-27, 2022 at the Luxe Sunset Boulevard Hotel, Los Angeles, CA. Ray Stachowiak, CEO, and Craig Tagawa, President and CFO, will present a corporate overview and meet with investors throughout the conference.

Key Points: 
  • Ray Stachowiak, CEO, and Craig Tagawa, President and CFO, will present a corporate overview and meet with investors throughout the conference.
  • The 2022 LD Micro Main Event XV will be held at the Luxe Sunset Boulevard Hotel in Los Angeles from October 25th to the 27th.
  • This three-day, investor conference is expected to feature around 200+ companies, presenting in half-hour increments, as well as private meetings.
  • [email protected]
    LD Micro aims to be the most crucial resource in the micro-cap world.

Global Trigeminal Neuralgia Therapeutics Market Research Report to 2027 - Featuring Alpha Therapeutics, Biogen, Karger and Pfizer Among Others - ResearchAndMarkets.com

Retrieved on: 
Monday, October 3, 2022
Health, Pharmaceutical, Trigeminal neuralgia, Value, Certification, CAGR, Market share analysis, Decision-making, R, COVID-19, Customer support, Growth, Therapy, USD, Strategic management, Business Growth Fund, Acquisition, Use, Investment, Retail, Medical device, Fine chemical

What are the inhibiting factors and impact of COVID-19 shaping the Global Trigeminal Neuralgia Therapeutics Market during the forecast period?

Key Points: 
  • What are the inhibiting factors and impact of COVID-19 shaping the Global Trigeminal Neuralgia Therapeutics Market during the forecast period?
  • Which are the products/segments/applications/areas to invest in over the forecast period in the Global Trigeminal Neuralgia Therapeutics Market?
  • What is the market share of the leading vendors in the Global Trigeminal Neuralgia Therapeutics Market?
  • What modes and strategic moves are considered suitable for entering the Global Trigeminal Neuralgia Therapeutics Market?

The Institut du Cancer Courlancy in Reims, France to Acquire the Advanced ZAP-X Gyroscopic Radiosurgery Platform

Retrieved on: 
Tuesday, September 27, 2022
Oncology, Health, Medical Devices, Neurology, Hospitals, Surgery, Radiology, TK, Radiation, Breast, Institute, Cranial nerves, Brainstem, Trigeminal neuralgia, Centre hospitalier universitaire Sainte-Justine, ICC, Radiosurgery, Prostate, Patient, CEO, ZAP, Stanford University, Lung, Radiation therapy, Hospital, Multimedia, Cancer, SRS, Medical imaging, Neurosurgery

ZAP Surgical Systems, Inc. today announced that the Institut du Cancer Courlancy (ICC) in Reims, France will add the latest advancement in non-invasive brain tumor treatments, the ZAP-X Gyroscopic Radiosurgery platform, to its current portfolio of cancer treatment technologies.

Key Points: 
  • ZAP Surgical Systems, Inc. today announced that the Institut du Cancer Courlancy (ICC) in Reims, France will add the latest advancement in non-invasive brain tumor treatments, the ZAP-X Gyroscopic Radiosurgery platform, to its current portfolio of cancer treatment technologies.
  • Radiosurgery, also referred to as SRS, is a well-studied and effective treatment for many brain cancers including primary and metastatic brain tumors.
  • For eligible indications, SRS is a completely non-invasive and pain-free alternative to expensive and often debilitating surgeries.
  • ZAP Surgical Systems, Inc. designs and manufactures the ZAP-X Gyroscopic Radiosurgery platform.

Lexicon Pharmaceuticals Highlights Scientific and Medical Presentations Relating to Its Successful Phase 2 Proof-Of-Concept Study of LX9211 in Painful Diabetic Neuropathy

Retrieved on: 
Tuesday, September 20, 2022
Pharmacokinetics, Trigeminal neuralgia, IASP, AAK1, Trial of the century, Food, Diabetic neuropathy, Efficacy, Neuropathic pain, Gene, Poster, Growth, Intellectual property, Form 10-K, Heart failure, Treatment, Therapy, Metabolism, Diabetes, U.S. Securities and Exchange Commission, Program, Patient, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Pain management, Protein, Bristol Myers Squibb, Nasdaq, Fast Track, Security (finance), Conference, GLOBE, National Conference, Annual report, Drug discovery, Disease, Pharmaceutical industry, Safety, Lexicon, Pain

THE WOODLANDS, Texas, Sept. 20, 2022 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced a series of scientific and medical presentations describing the progression of its investigational drug LX9211 from discovery to translation in a clinical proof-of-concept study.

Key Points: 
  • We are excited to present these findings to the medical and scientific community and expect to communicate additional LX9211 clinical and preclinical data as they become available.
  • RELIEF-DPN-1 was a Phase 2 randomized, double-blind, placebo-controlled, parallel-group, multicenter study evaluating the efficacy, safety and pharmacokinetics of LX9211 in the treatment of painful diabetic neuropathy, also referred to as diabetic peripheral neuropathic pain.
  • The RELIEF-DPN-1 study was the first of two Phase 2 proof-of-concept studies evaluating LX9211 in neuropathic pain.
  • LX9211 has received Fast Track designation from the U.S. Food and Drug Administration for the development in diabetic peripheral neuropathic pain.

Noema Pharma Announces Completion of Enrollment in the Trigeminal Neuralgia Electronic Diary (TNED) Validation Study

Retrieved on: 
Tuesday, September 6, 2022
Trigeminal nerve, UCL, University College Hospital, Pain, Trigeminal neuralgia, Noema, Sofinnova, Glutamate (neurotransmitter), Seizure, Brain, LIBRA, Sensation, Diagnosis, Self-assessment, Pain scale, Neuropathic pain, GLOBE, Â, Nerve injury, Company, Diary, Tourette syndrome, Data collection, Face, PDE10A, Polaris Partners, CNS, UCLH, Tuberous sclerosis complex tumor suppressors, Patient, Basimglurant, Medical device, Pharmaceutical industry, Research, Biotechnology

BASEL, Switzerland and BOSTON, Sept. 06, 2022 (GLOBE NEWSWIRE) -- Noema Pharma, a clinical-stage biotech company targeting debilitating central nervous system (CNS) indications, today announces it has completed participant enrollment and data collection in the validation study of a novel Trigeminal Neuralgia Electronic Diary (TNED).

Key Points: 
  • BASEL, Switzerland and BOSTON, Sept. 06, 2022 (GLOBE NEWSWIRE) -- Noema Pharma, a clinical-stage biotech company targeting debilitating central nervous system (CNS) indications, today announces it has completed participant enrollment and data collection in the validation study of a novel Trigeminal Neuralgia Electronic Diary (TNED).
  • Thirty participants with a confirmed diagnosis of trigeminal neuralgia (TN) volunteered to complete the electronic diary.
  • While the analysis of the validation data is ongoing, the electronic diary was generally found to be easy to use and enabled participants to accurately describe the burden of trigeminal neuralgia (TN).
  • In addition to being patient friendly and easy to use, TNED is the first electronic diary designed specifically for people who suffer from TN.

American Shared Hospital Services Strengthens Management Team with Appointment of Peter Gaccione as Chief Operating Officer

Retrieved on: 
Thursday, September 1, 2022
Well, COO, CA, Security (finance), COVID-19, University, Cancer, NYSE, Trigeminal neuralgia, Management, Leeds Gamma Knife Centre, CMS, Proton therapy, HVS Global Hospitality Services, Radiation, Physician, IMRT, Well known, Century, Neuroscience, Radiosurgery, Hospital, Pain scale, U.S. Securities and Exchange Commission, Union of Sales and Marketing Professionals, GLOBE, Annual general meeting, Leadership, Company, Elekta, Malignancy, IGRT, Risk, AMS, Pectus carinatum, Annual report, Marketing, Cardiology, Industry, Growth, Brachytherapy, Medical imaging

SAN FRANCISCO, CA, Sept. 01, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – American Shared Hospital Services (NYSE American: AMS) (the “Company”), a leading provider of turnkey technology solutions for stereotactic radiosurgery and advanced radiation therapy equipment, facilities, and services, today announced the appointment of Peter Gaccione as Chief Operating Officer (COO), effective September 7th, 2022. Mr. Gaccione assumes the COO position from Craig Tagawa who remains the Company’s President and Chief Financial Officer.

Key Points: 
  • Mr. Gaccione assumes the COO position from Craig Tagawa who remains the Companys President and Chief Financial Officer.
  • Ray Stachowiak, Chief Executive Officer, commented, Were excited to welcome Peter Gaccione as Chief Operating Officer of American Shared Hospital Services.
  • His addition expands and strengthens the management team and the outlook for growth of the Company.
  • About American Shared Hospital Services (NYSE American: AMS)
    American Shared Hospital Services is a leading provider of turnkey technology solutions for stereotactic radiosurgery and advanced radiation therapy equipment, facilities, and services.

Neurosurgery One in Littleton, Colorado Treats First Patient with ZAP-X Gyroscopic Radiosurgery

Retrieved on: 
Monday, August 29, 2022
Oncology, Health, Medical Devices, Neurology, Hospitals, Surgery, Radiology, Schwannoma, Meningioma, Vestibular schwannoma, Nervous system, Skiing, CEO, Technology, Pain, Trigeminal neuralgia, Rocky Mountains, Brain, Edwards, Colorado, Dizziness, CO, WBRT, SRS, Radiation, Male, Radiation therapy, Quality of life, Multimedia, MD, TK, Stanford University, Hearing loss, ZAP, Patient, Medical imaging, Dentistry, Neurosurgery

ZAP Surgical Systems, Inc. today announced that Denver-based Neurosurgery One became the first provider in the Rocky Mountain region to treat patients using the ZAP-X Gyroscopic Radiosurgery platform.

Key Points: 
  • ZAP Surgical Systems, Inc. today announced that Denver-based Neurosurgery One became the first provider in the Rocky Mountain region to treat patients using the ZAP-X Gyroscopic Radiosurgery platform.
  • Neurosurgery One doctors are now performing stereotactic radiosurgery (SRS) using ZAP-X in an outpatient facility in the south Denver metro area of Littleton, Colorado.
  • View the full release here: https://www.businesswire.com/news/home/20220829005018/en/
    William (Bill) Lawson, of Edwards, CO, was the first patient in the Rocky Mountain region to undergo ZAP-X Gyroscopic Radiosurgery at Neurosurgery One in Littleton.
  • He was treated for an acoustic neuroma, a benign tumor on the main nerve leading between the inner ear and brain.

American Shared Hospital Services Reports 12.5% Period-over-Period Increase in Second Quarter 2022 Revenue

Retrieved on: 
Thursday, August 11, 2022
Proton, Cyprus Securities and Exchange Commission, Leeds Gamma Knife Centre, Hospital, Risk, Income, NYSE, Proton therapy, GLOBE, HVS Global Hospitality Services, Pectus carinatum, CA, Annual general meeting, Growth, Webcast, Traction, Malignancy, Annual report, Home After Three Months Away, Security (finance), Radiosurgery, Marketing, IGRT, EBITDA, Century, Orlando Health, COVID-19, Company, Contract, SAN, IMRT, Depreciation, CMS, Loss, GAAP, Trigeminal neuralgia, PBRT, AMS, Fossil fuel, Lithium, Video game, Health insurance, Pharmaceutical industry, Online gambling, Medical imaging, Bank

SAN FRANCISCO, CA, Aug. 11, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- American Shared Hospital Services (NYSE American: AMS) (the "Company"), a leading provider of turnkey technology solutions for stereotactic radiosurgery and advanced radiation therapy equipment and services, today announced financial results for the second quarter ending June 30, 2022.

Key Points: 
  • Operating income for the second quarter of 2022 was $793,000 compared to operating income of $352,000 in the second quarter of 2021, an increase of 125%.
  • Adjusted EBITDA, a non-GAAP financial measure, was $2,129,000 for the second quarter of 2022, compared to $1,829,000 for the second quarter of 2021, an increase of 16.4%.
  • Net incomeattributable to American Shared Hospital Servicesin the second quarter 2022 was $497,000, or $0.08 per diluted share, compared to a net loss of $87,000, or ($0.01) per diluted share, for the second quarter of 2021.
  • Adjusted EBITDA, a non-GAAP financial measure, was $2,129,000for the second quarter of 2022, compared to $1,829,000 for the second quarter of 2021, an increase of 16.4%.

American Shared Hospital Services Announces Second Quarter 2022 Earnings Conference Call

Retrieved on: 
Friday, August 5, 2022
Company, CA, SAN, IMRT, Malignancy, Trigeminal neuralgia, Pain scale, NYSE, Proton therapy, GLOBE, Radiosurgery, IGRT, AMS, Pectus carinatum, Medical imaging

SAN FRANCISCO, CA, Aug. 05, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – American Shared Hospital Services (NYSE American: AMS) (the "Company"), a leading provider of turnkey technology solutions for stereotactic radiosurgery and advanced radiation therapy equipment and services, today announced that the Company will hold a quarterly conference call to discuss its second quarter 2022 financial results on Friday, August 12, 2022 at 12:00 pm ET / 9:00 am PT. The second quarter 2022 financial results press release will be issued after the market close on Thursday, August 11, 2022.

Key Points: 
  • SAN FRANCISCO, CA, Aug. 05, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire American Shared Hospital Services (NYSE American: AMS) (the "Company"), a leading provider of turnkey technology solutions for stereotactic radiosurgery and advanced radiation therapy equipment and services, today announced that the Company will hold a quarterly conference call to discuss its second quarter 2022 financial results on Friday, August 12, 2022 at 12:00 pm ET / 9:00 am PT.
  • The second quarter 2022 financial results press release will be issued after the market close on Thursday, August 11, 2022.
  • To participate, please call 1 (844) 413-3972 at least 10 minutes prior to the start of the call and ask to join the American Shared Hospital Services call.
  • About American Shared Hospital Services (NYSE American: AMS)
    American Shared Hospital Services is a leading provider of turnkey technology solutions for stereotactic radiosurgery and advanced radiation therapy equipment and services.